Anticoagulation Strategies in COVID-Associated Coagulopathy

Time Stamps

00:00 Podcast Intro

00:40 What is COVID-associated coagulopathy and why is it important to recognize this?

02:45 How is this coagulopathy similar to or different from other coagulopathies that we commonly see in clinical practice?

04:30 Is there recommended testing for COVID-associated coagulopathy?

06:30 Can you explain what the soluble fibrin monomer test is?

08:09 How is COVID-associated coagulopathy managed in terms on prophylactic anticoagulation, therapeutic anticoagulation, and prophylactic transfusion?

14:23 What are a few lessons that you have learned during this pandemic so far?

Resources:

1.       F.A. Klok, M.J.H.A. Kruip, N.J.M. van der Meer, et al., Incidence of thrombotic complications in critically ill ICU patients with COVID-19,Thrombosis Research (2020), https://doi.org/10.1016/j.thromres.2020.04.013  

2.       doi:10.1111/JTH.14810